Department of Oncology, Lund University, Lund, Sweden.
Int J Cancer. 2010 Aug 15;127(4):961-7. doi: 10.1002/ijc.25091.
A large proportion of women with lymph node negative breast cancer do not benefit from chemotherapy. Proliferation markers have been shown to recognize patients at high risk for recurrence. The Ki67 protein has recently been included in the St Gallen guidelines. The authors investigated the prognostic importance of cyclin B1 in node negative breast cancer and included a study of reproducibility. In a population-based case-control study, 190 women who died from breast cancer were defined as cases and 190 women alive at the time for the corresponding case's death were defined as controls. Inclusion criteria were tumor size </=50 mm, no lymph node metastases, and no adjuvant chemotherapy. Tumor tissue was immunostained for cyclin B1. Two investigators (EN-M and AK) evaluated the staining independently by counting approximately 100, 200, 500, and 1000 cells. Cyclin B1 was statistically significantly associated to breast cancer death, in both uni- and multivariate analyses (adjusted for tumor size, age, and endocrine therapy), with odds ratios 2-3 for both investigators. The agreement between the two investigators was good to very good, regardless of the number of counted cells (kappa values between 0.74 and 0.82). Cyclin B1 is a prognostic factor for breast cancer death in a population-based node negative patient cohort which can identify high-risk patients with a good to very good reproducibility.
很大一部分淋巴结阴性乳腺癌患者并未从化疗中获益。增殖标志物已被证明可识别高复发风险的患者。Ki67 蛋白最近已被纳入圣加仑指南。作者研究了细胞周期蛋白 B1 在淋巴结阴性乳腺癌中的预后意义，并进行了可重复性研究。在一项基于人群的病例对照研究中，190 名死于乳腺癌的女性被定义为病例，190 名在相应病例死亡时存活的女性被定义为对照。纳入标准为肿瘤大小 </=50mm，无淋巴结转移，无辅助化疗。肿瘤组织用细胞周期蛋白 B1 进行免疫染色。两名研究人员（EN-M 和 AK）通过计数大约 100、200、500 和 1000 个细胞来独立评估染色。细胞周期蛋白 B1 在单变量和多变量分析中均与乳腺癌死亡显著相关（调整肿瘤大小、年龄和内分泌治疗），两位研究人员的比值比均为 2-3。无论计数的细胞数量如何，两位研究人员之间的一致性都很好到非常好（kappa 值在 0.74 到 0.82 之间）。细胞周期蛋白 B1 是基于人群的淋巴结阴性患者队列中乳腺癌死亡的预后因素，可识别出具有良好到非常好可重复性的高危患者。
